Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5946577 | Atherosclerosis | 2014 | 8 Pages |
Abstract
Epicatechin attenuates development of atherosclerosis and impairs lesion progression from mild to severe lesions in absence of an effect on dyslipidaemia. The observed reduction of circulating inflammatory risk factors by epicatechin (e.g. SAA, human-CRP), as well as its local anti-inflammatory activity in the vessel wall, provide a rationale for epicatechin's anti-atherogenic effects.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Martine Morrison, Roel van der Heijden, Peter Heeringa, Eric Kaijzel, Lars Verschuren, Rune Blomhoff, Teake Kooistra, Robert Kleemann,